Ozempic and Sleep Apnea: What GLP-1 Weight Loss Means for CPAP Users

Reading Time: 10 minutes

Sleep apnea is one of those conditions that hides in plain sight. According to a 2024 analysis from the Canadian Longitudinal Study on Aging, roughly 28% of Canadian adults aged 45 to 85 have moderate to severe obstructive sleep apnea (OSA). Yet only about 3% have actually been diagnosed. That means for every person using a CPAP machine at night, several more are sleeping beside them with the same problem and no idea it exists.

So when headlines started appearing about Ozempic and similar GLP-1 weight loss medications reducing sleep apnea symptoms, it caught the attention of sleep researchers, physicians, and the millions of Canadians who wake up every morning feeling like they barely slept.

Here is what the clinical evidence actually shows, what it does not show, and what it might mean for your sleep.

How Weight Affects Sleep Apnea

Before we talk about medications, it helps to understand why weight and sleep apnea are so closely linked.

Obstructive sleep apnea happens when the soft tissues in your throat relax during sleep and partially or completely block your airway. Each blockage is called an "apnea event," and your body briefly wakes you up (often without you remembering) to resume breathing. This can happen dozens or even hundreds of times per night.

Excess weight contributes to this in several ways:

• Neck fat deposits: Fat tissue around the neck and throat compresses the airway from the outside. A neck circumference greater than 17 inches in men or 16 inches in women is a significant risk factor for OSA.
• Tongue fat: Research from the University of Pennsylvania found that weight gain causes fat to infiltrate the tongue itself, which pushes the airway structures downward and narrows the breathing passage.
• Abdominal pressure: Excess abdominal weight compresses the lungs and diaphragm, reducing lung volume and making the upper airway more collapsible during sleep.

This is why weight loss, through any method, has long been recommended as a first-line approach alongside CPAP therapy. The question with GLP-1 medications is whether the significant, sustained weight loss they produce translates into measurable sleep apnea improvement.

The answer, based on the latest trials, is yes. With important caveats.

What GLP-1 Medications Actually Do

GLP-1 receptor agonists (glucagon-like peptide-1) are a class of injectable medications originally developed for type 2 diabetes. They mimic a natural hormone that regulates appetite, blood sugar, and digestion. The most well-known names include:

• Semaglutide (brand names Ozempic for diabetes, Wegovy for weight management)
• Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight management)
• Liraglutide (brand name Saxenda for weight management)

These medications help people lose a meaningful amount of weight. Clinical trials show semaglutide produces average weight loss of about 15% of body weight over 16 months, while tirzepatide has shown weight loss of 16% to 17% over 52 weeks.

That kind of weight loss has downstream effects on almost every obesity-related condition, including sleep apnea.

The SURMOUNT-OSA Trial: Real Numbers

The results were significant. In Trial 1 (participants not using CPAP), the apnea-hypopnea index (AHI, the number of breathing interruptions per hour) dropped by an average of 25.3 events per hour with tirzepatide, compared to just 5.3 events per hour with placebo. That is a treatment difference of 20 fewer breathing interruptions every hour of sleep.

Trial 2 (participants using CPAP alongside the medication) showed even larger reductions: AHI dropped by 29.3 events per hour with tirzepatide versus 5.5 with placebo, a difference of 23.8 events per hour.

In percentage terms:

• Trial 1: AHI reduced by 47.7%
• Trial 2: AHI reduced by 56.2%
• Hypoxic burden (time spent with low oxygen levels during sleep) dropped by 61% to 70%
• Body weight decreased by 16% to 17%
• Systolic blood pressure dropped by 3.7 to 7.6 mmHg

Perhaps most striking: up to 50% of tirzepatide participants achieved what researchers call "disease resolution or clinically meaningful improvement," defined as fewer than 5 AHI events per hour, or 5 to 14 events with an Epworth Sleepiness Scale score of 10 or less.

Based on these results, the FDA approved Zepbound (tirzepatide) in December 2024 as the first-ever prescription medication indicated for moderate-to-severe obstructive sleep apnea in adults with obesity.

What About Semaglutide (Ozempic/Wegovy)?

Semaglutide has not been studied in a dedicated large-scale OSA trial the way tirzepatide has. However, the earlier SCALE Sleep Apnea trial tested liraglutide (an older GLP-1) and found a reduction of 12.2 AHI events per hour over 32 weeks, compared to 6.1 with placebo. A meta-analysis of all GLP-1 receptor agonist studies found an average AHI reduction of roughly 14.5 events per hour across the drug class.

The research suggests the benefit comes primarily from weight loss rather than a direct effect on the airway. Any GLP-1 medication that produces substantial weight loss is likely to improve OSA severity, though tirzepatide currently has the strongest evidence.

Why CPAP Is Still the Gold Standard

Here is the part that matters most, and where the headlines can be misleading.

GLP-1 medications are not approved as a treatment for sleep apnea itself. Zepbound's FDA approval is specifically for OSA in adults with obesity, and it works by addressing the obesity component. It does not directly treat the airway obstruction.

Research from bariatric surgery outcomes reinforces this point. Even after significant surgical weight loss, approximately half of patients still require CPAP. Weight loss helps. It may be a meaningful part of a treatment plan. But it is not a standalone solution for most people with moderate-to-severe OSA.

If you are currently using CPAP therapy, please do not discontinue it based on weight loss from any medication. That decision belongs to you and your sleep physician, guided by a follow-up sleep study showing your AHI has improved enough to safely reduce or stop PAP therapy.

Getting Diagnosed in Ontario

Once diagnosed, CPAP equipment in Ontario is partially covered through the Assistive Devices Program (ADP). ADP typically covers 75% of the approved device cost, with the remaining 25% as your responsibility (often covered by private insurance if you have it). You will need a prescription from a qualified sleep physician and must meet ADP's medical necessity criteria.

For Brantford-area residents, your family doctor is the starting point. The Brant Community Healthcare System and nearby Hamilton Health Sciences both have sleep medicine programs. GLP-1 medications, if appropriate for your situation, would be prescribed separately through your physician for weight management.

Your Sleep Environment Still Matters

Whether you are using CPAP, exploring GLP-1 medications for weight management, or both, your sleep setup plays a real role in managing sleep apnea symptoms.

Head-of-Bed Elevation

A study published in Sleep and Breathing found that elevating the head of the bed by just 7.5 degrees reduced AHI by 31.8% in patients with mild to moderate OSA. Another study found that 20 to 30 degrees of head elevation reduced sleep apnea events by up to 45% in positional OSA patients.

This is where adjustable bed frames become genuinely useful for sleep apnea patients, not as a marketing gimmick, but as a clinically supported tool. An adjustable base lets you set and save a precise elevation angle, keeping your airway more open through gravity alone. It also works alongside CPAP therapy, not against it.

Mattress and Sleep Position

Side sleeping reduces the gravitational pull on throat tissues and is consistently recommended for OSA patients. A mattress that supports CPAP use and side sleeping should offer enough pressure relief at the shoulder and hip to make lateral sleeping comfortable all night.

GLP-1 medications can also cause night sweats as a side effect, so breathability in your mattress and bedding is worth considering if you are taking these medications.

CPAP-Friendly Sleep Setup

If you use CPAP, an adjustable base with a flat headboard area keeps your hose and mask positioned properly. Many of our customers with sleep apnea use the adjustable bed features designed specifically for CPAP users, including memory positions that let you save your ideal elevation angle and return to it every night.

Related Reading

• Sleep Apnea and Your Mattress: Sleep Position, CPAP Setup, and What Actually Helps
• Adjustable Beds for Sleep Apnea in Canada
• Snoring: Causes, Sleep Position, and When It Is More Than Just Snoring
• Best Adjustable Bed Canada 2026
• Night Sweats Guide